Correlation Between SCI Pharmtech and Sinphar Pharmaceutical

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both SCI Pharmtech and Sinphar Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SCI Pharmtech and Sinphar Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between SCI Pharmtech and Sinphar Pharmaceutical Co, you can compare the effects of market volatilities on SCI Pharmtech and Sinphar Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SCI Pharmtech with a short position of Sinphar Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of SCI Pharmtech and Sinphar Pharmaceutical.

Diversification Opportunities for SCI Pharmtech and Sinphar Pharmaceutical

-0.47
  Correlation Coefficient

Very good diversification

The 3 months correlation between SCI and Sinphar is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding SCI Pharmtech and Sinphar Pharmaceutical Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sinphar Pharmaceutical and SCI Pharmtech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SCI Pharmtech are associated (or correlated) with Sinphar Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sinphar Pharmaceutical has no effect on the direction of SCI Pharmtech i.e., SCI Pharmtech and Sinphar Pharmaceutical go up and down completely randomly.

Pair Corralation between SCI Pharmtech and Sinphar Pharmaceutical

Assuming the 90 days trading horizon SCI Pharmtech is expected to generate 1.5 times more return on investment than Sinphar Pharmaceutical. However, SCI Pharmtech is 1.5 times more volatile than Sinphar Pharmaceutical Co. It trades about 0.13 of its potential returns per unit of risk. Sinphar Pharmaceutical Co is currently generating about -0.13 per unit of risk. If you would invest  8,750  in SCI Pharmtech on September 12, 2024 and sell it today you would earn a total of  650.00  from holding SCI Pharmtech or generate 7.43% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

SCI Pharmtech  vs.  Sinphar Pharmaceutical Co

 Performance 
       Timeline  
SCI Pharmtech 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in SCI Pharmtech are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, SCI Pharmtech may actually be approaching a critical reversion point that can send shares even higher in January 2025.
Sinphar Pharmaceutical 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sinphar Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Sinphar Pharmaceutical is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

SCI Pharmtech and Sinphar Pharmaceutical Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with SCI Pharmtech and Sinphar Pharmaceutical

The main advantage of trading using opposite SCI Pharmtech and Sinphar Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SCI Pharmtech position performs unexpectedly, Sinphar Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sinphar Pharmaceutical will offset losses from the drop in Sinphar Pharmaceutical's long position.
The idea behind SCI Pharmtech and Sinphar Pharmaceutical Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Complementary Tools

Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Fundamental Analysis
View fundamental data based on most recent published financial statements
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account